Human ULBP-2/5/6 PerCP-conjugated Antibody Summary
Accession # Q9BZM5
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of ULBP-2/5/6 in HT1080 Human Cell Line by Flow Cytometry. HT1080 human fibrosarcoma cell line was stained with Mouse Anti-Human ULBP-2/5/6 PerCP‑conjugated Monoclonal Antibody (Catalog # FAB1298C, filled histogram) or isotype control antibody (Catalog # IC003C, open histogram). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. The name ULBP derives from the original identification of three proteins, ULBP-1, -2, and -3, as ligands for the human cytomegalovirus glycoprotein UL16; they were designated UL16 binding proteins (ULBP). The genes for ULBPs reside in a cluster of ten related genes, six of which encode potentially functional glycoproteins. ULBP-2 has also been described under the names RaeT1H (retinoic acid early transcript), NKG2DL2, and ALCAN-alpha. ULBP-5 also known as RaeT1G and ULBP-6 also known as RaeT1L. These proteins are distantly related to MHC class I proteins, but they possess only the alpha 1 and alpha 2 Ig-like domains, and they have no capacity to bind peptide or interact with beta 2-microglobulin. Some family members, including ULBP-2, are anchored to the membrane via a GPI-linkage, whereas others have transmembrane domains. Engagement of NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. The ULBPs are expressed on some tumor cells and have been implicated in tumor surveillance. Over aa 26-217, ULBP-2 shares 92% and 95% aa sequence identity with the human ULBP-5 and ULBP-6, respectively.
- Cosman, D. et al. (2001) Immunity 14:123.
- Kubin, M. et al. (2001) Eur. J. Immunol. 31:1428.
- Sutherland, C. et al. (2002) J. Immunol. 168:671.
- Steinle, A. et al. (2001) Immunogenetics 53:279.
- Sutherland, C. et al. (2001) Immunol. Rev. 181:185.
- Pende, D. et al. (2002) Cancer Res. 62:6178.
- Radosavljevic, M. et al. (2002) Genomics 79:114.
- NKG2D and its Ligands (2002) www.RnDSystems.com.
Citation for Human ULBP-2/5/6 PerCP-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
Authors: I Truxova, L Kasikova, C Salek, M Hensler, D Lysak, P Holicek, P Bilkova, M Holubova, X Chen, R Mikyskova, M Reinis, M Kovar, B Tomalova, JP Kline, L Galluzzi, R Spisek, J Fucikova
Sample Types: Whole Cells
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human ULBP-2/5/6 PerCP-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human ULBP-2/5/6 PerCP-conjugated Antibody and earn rewards!
Have you used Human ULBP-2/5/6 PerCP-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image